David Barros-Sierra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Barros-Sierra has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Marcela Tamayo-Ortiz
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA
3 shared publications - Héctor Osiris Gutiérrez-Díaz
Dirección de Prestaciones Económicas y Sociales, Instituto Mexicano del Seguro Social. Ciudad de México, Mexico...
2 shared publications - Mauricio Hernández-Ávila
Directorate of Economic and Social Benefits, Instituto Mexicano del Seguro Social, Mexico City, Mexico
2 shared publications - Celia Mercedes Alpuche-Aranda
Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México...
1 shared publication - Célida Duque-Molina
Instituto Mexicano del Seguro Social, Dirección de Prestaciones Médicas. Ciudad de México, México
1 shared publication - Dwight Dyer-Leal
Secretaría de Salud. Mexico City, Mexico...
1 shared publication
Latest Publications
- Open Access
- 8 December 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (1, ene-feb) , 8-10
Seroprevalencia a SARSCoV- 2 en trabajadores de los sectores esencial (comercio) y no esencial (educativo) durante 2021 en México
- 8 December 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (1, ene-feb) , 8-10
Open AccessSeroprevalencia a SARSCoV- 2 en trabajadores de los sectores esencial (comercio) y no esencial (educativo) durante 2021 en México
- Open Access
- 8 December 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (1, ene-feb) , 85-94
The Omicron wave in Mexico: vaccine protection against progression to severe Covid-19 in SARS-CoV-2-infected workers
Objective. To assess the effectiveness of seven Covid-19 vaccines in preventing disease progression (DP) using data from national private sector workers during the Omicron wave in Mexico from January 2 to March 5, 2022. Materials and methods. This study employed an administrative retrospective cohort design, analyzing DP (hospitalization or death due to respiratory disease) among workers who filed a respiratory short-term disability claim and tested positive for SARS-CoV-2. Risk ratios (RRadj) were estimated using Poisson regression models adjusted for various factors. Results. Vaccinated individuals had a lower risk of hospitalization and death compared with unvaccinated individuals. The overall RRadj for hospitalization and death were 0.36 (95%CI 0.32, 0.41) and 0.24 (0.17, 0.33), respectively. When evaluating vaccines individually, the RRadj for hospitalization were as follows Pfizer BioNTech 0.27 (95%CI 0.22, 0.33), Moderna 0.29 (95%CI 0.15, 0.57), Sinovac 0.32 (95%CI 0.25, 0.41), AstraZeneca 0.39 (95%CI 0.34, 0.46), Sputnik 0.39 (95%CI 0.28, 0.53), CanSino 0.41 (95%CI 0.24, 0.7), and Janssen 0.53 (95%CI 0.39, 0.72). The RRadj for death were as follows: Pfizer BioNTech 0.12 (95%CI 0.07, 0.19), Sputnik 0.15 (95%CI 0.06, 0.38), Sinovac 0.29 (95%CI 0.16, 0.53), AstraZeneca 0.30 (95%CI 0.20, 0.44), CanSino 0.38 (95%CI 0.1, 1.4), and Janssen 0.50 (95%CI 0.26, 0.97). Conclusion. Covid-19 vaccines significantly reduced the risk of severe disease during the Omicron wave in Mexico.
- 8 December 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (1, ene-feb) , 85-94
Open AccessThe Omicron wave in Mexico: vaccine protection against progression to severe Covid-19 in SARS-CoV-2-infected workers
Objective. To assess the effectiveness of seven Covid-19 vaccines in preventing disease progression (DP) using data from national private sector workers during the Omicron wave in Mexico from January 2 to March 5, 2022. Materials and methods. This study employed an administrative retrospective cohort design, analyzing DP (hospitalization or death due to respiratory disease) among workers who filed a respiratory short-term disability claim and tested positive for SARS-CoV-2. Risk ratios (RRadj) were estimated using Poisson regression models adjusted for various factors. Results. Vaccinated individuals had a lower risk of hospitalization and death compared with unvaccinated individuals. The overall RRadj for hospitalization and death were 0.36 (95%CI 0.32, 0.41) and 0.24 (0.17, 0.33), respectively. When evaluating vaccines individually, the RRadj for hospitalization were as follows Pfizer BioNTech 0.27 (95%CI 0.22, 0.33), Moderna 0.29 (95%CI 0.15, 0.57), Sinovac 0.32 (95%CI 0.25, 0.41), AstraZeneca 0.39 (95%CI 0.34, 0.46), Sputnik 0.39 (95%CI 0.28, 0.53), CanSino 0.41 (95%CI 0.24, 0.7), and Janssen 0.53 (95%CI 0.39, 0.72). The RRadj for death were as follows: Pfizer BioNTech 0.12 (95%CI 0.07, 0.19), Sputnik 0.15 (95%CI 0.06, 0.38), Sinovac 0.29 (95%CI 0.16, 0.53), AstraZeneca 0.30 (95%CI 0.20, 0.44), CanSino 0.38 (95%CI 0.1, 1.4), and Janssen 0.50 (95%CI 0.26, 0.97). Conclusion. Covid-19 vaccines significantly reduced the risk of severe disease during the Omicron wave in Mexico.
- Open Access
- 15 July 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 65 (4, jul-ago) , 334-343
SARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area
Objective. To characterize the impact of SARS-CoV-2 infection in workers from an essential large-scale company in the Greater Mexico City Metropolitan Area using point prevalence of acute infection, point prevalence of past infection through serum antibodies and respiratory disease short-term disability claims (RD-STDC). Materials and methods. Four randomized surveys, three during 2020 before and one after (December 2021) vaccines' availability. Outcomes: point prevalence of acute infection through saliva PCR (polymerase chain reaction) testing, point prevalence of past infection through serum antibodies against Covid-19, RD-STDC and prevalence of symptoms during the previous six months. Results. Prevalence of SARS-CoV-2 cases was 1.29-4.88%, on average, a quarter of participants pre-vaccination were seropositive; over half of participants with a RD-STDC had antibodies. The odds of having antibodies were 6-7 times more among workers with an RD-STDC. Conclusions. High antibody levels against Covid-19 in this study population reflects that coverage is high among workers in this industry. STDCs are a useful tool to track workplace epidemics.
- 15 July 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 65 (4, jul-ago) , 334-343
Open AccessSARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area
Objective. To characterize the impact of SARS-CoV-2 infection in workers from an essential large-scale company in the Greater Mexico City Metropolitan Area using point prevalence of acute infection, point prevalence of past infection through serum antibodies and respiratory disease short-term disability claims (RD-STDC). Materials and methods. Four randomized surveys, three during 2020 before and one after (December 2021) vaccines' availability. Outcomes: point prevalence of acute infection through saliva PCR (polymerase chain reaction) testing, point prevalence of past infection through serum antibodies against Covid-19, RD-STDC and prevalence of symptoms during the previous six months. Results. Prevalence of SARS-CoV-2 cases was 1.29-4.88%, on average, a quarter of participants pre-vaccination were seropositive; over half of participants with a RD-STDC had antibodies. The odds of having antibodies were 6-7 times more among workers with an RD-STDC. Conclusions. High antibody levels against Covid-19 in this study population reflects that coverage is high among workers in this industry. STDCs are a useful tool to track workplace epidemics.